Patrik Jonsson Biography and Net Worth

Executive Vice President and President of Eli Lilly and Company

Patrik Jonsson (he/him/his) is executive vice president of Eli Lilly and Company and president of Lilly International.

Patrik served most recently as executive vice president and president of Lilly Cardiometabolic Health, and president, Lilly USA and the Global Customer Office, after roles as executive vice president and president of Lilly Immunology and Lilly Bio-Medicines.

Since joining the company in 1990 as a sales representative, Patrik has held leadership positions in sales, marketing and general management. He served as managing director of Lilly Sweden and later of Scandinavia, and as president and general manager of Lilly’s Italy Hub before being named president and general manager of Lilly Japan in 2014.

Patrik is a business graduate from Lund University School of Economics and Management in Sweden.

Patrik is a member of the Board of the European Federation of Pharmaceutical Industries (EFPIA) and Chair of the EFPIA International Board Sponsored Committee.

What is Patrik Jonsson's net worth?: The estimated net worth of Patrik Jonsson is at least $66.44 million as of August 17th, 2026. Mr. Jonsson owns 54,147 shares of Eli Lilly and Company stock worth more than $66,444,163 as of August 19th. This net worth evaluation does not reflect any other assets that Mr. Jonsson may own. Learn More about Patrik Jonsson's net worth.
How do I contact Patrik Jonsson?: The corporate mailing address for Mr. Jonsson and other Eli Lilly and Company executives is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. Eli Lilly and Company can also be reached via phone at (317) 276-2000 and via email at [email protected]. Learn More on Patrik Jonsson's contact information.
Has Patrik Jonsson been buying or selling shares of Eli Lilly and Company?: During the last quarter, Patrik Jonsson has sold $7,638,150.00 in Eli Lilly and Company stock. Most recently, Patrik Jonsson sold 6,500 shares of the business's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a transaction totalling $7,638,150.00. Following the completion of the sale, the executive vice president now directly owns 54,147 shares of the company's stock, valued at $63,628,139.70. Learn More on Patrik Jonsson's trading history.
Who are Eli Lilly and Company's active insiders?: Eli Lilly and Company's insider roster includes Anat Ashkenazi (Sr. VP & CFO ), Melissa Barnes (SVP), Enrique Conterno (SVP), Stephen Fry (SVP), J. Fyrwald (Director), Michael Harrington (VP), Jamere Jackson (Director), Patrik Jonsson (Executive Vice President and President), Susan Mahony (SVP), Johna Norton (EVP), Myles O'Neill (SVP), Derica Rice (EVP), David Ricks (CEO), Marschall Runge (Director), Aarti Shah (SVP), Christi Shaw (SVP), Jeffrey Simmons (SVP), Daniel Skovronsky (SVP), Joshua Smiley (CFO), Gabrielle Sulzberger (Director), Jackson Tai (Director), Jacob Van Naarden (Sr. VP), Alonzo Weems (EVP), Anne White (SVP), Ilya Yuffa (SVP), Donald Zakrowski (CAO), and Alfonso Zulueta (SVP). Learn More on Eli Lilly and Company's active insiders.
Are insiders buying or selling shares of Eli Lilly and Company?: In the last year, insiders at the sold shares 3 times. They sold a total of 13,500 shares worth more than $15,958,170.00. The most recent insider tranaction occured on August, 17th when EVP Patrik Jonsson sold 6,500 shares worth more than $7,638,150.00. Insiders at Eli Lilly and Company own 0.1% of the company. Learn More about insider trades at Eli Lilly and Company.
Information on this page was last updated on 8/17/2026.

Patrik Jonsson Insider Trading History at Eli Lilly and Company

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/17/2026	Sell	6,500	$1,175.10	$7,638,150.00	54,147
6/1/2023	Sell	6,000	$429.46	$2,576,760.00	36,941

Patrik Jonsson Buying and Selling Activity at Eli Lilly and Company

Eli Lilly and Company Company Overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Today's Range

Now: $1,227.11

$1,194.01

$1,228.47

50 Day Range

MA: $1,173.20

$1,098.78

$1,233.32

2 Week Range

Now: $1,227.11

$685.15

$1,249.45

Volume

2,506,238 shs

Average Volume

2,665,699 shs

Market Capitalization

$1.16 trillion

P/E Ratio

41.18

Dividend Yield

0.59%

Beta

0.51